Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 7
Submit an article Journal homepage
72
Views
7
CrossRef citations to date
0
Altmetric
Review

Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm

Eric T Wong Beth Israel Deaconess Medical Center, Brain Tumour Center & Neuro-Oncology Unit, Department of Neurology, 330 Brookline Avenue, Boston, MA 02215, USA. [email protected]
Pages 1107-1114 | Published online: 15 Jun 2005

Bibliography

  • DEANGELIS LM, YAHALOM J, THALER HT et al.: Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. (1992) 10:635–643.
  • ••This is the first clinical paper demonstrating that chemotherapy is the primary treatment for primary CNS lymphomas, whereas radiation is for consolidation.
  • MCLAUGHLIN P, VELASQUEZ WS, REDMAN JR et al.: Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J. Natl. Cancer Inst. (1988) 80:1408–1412.
  • HERRLINGER U, BRUGGER W, BAMBERG M et al.: PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology (2000) 54:1707–1708.
  • CIORDIA R, HOCHBERG FH, BATCHELOR TT: Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma. Proc. Am. Soc. Clin. Oncol. (2000) 19:165a.
  • WONG ET: Correspondence: immunochemotherapy with rituximab and temozolomide for central nervous system lymphoma. Cancer (2004) 101:2900–2902.
  • DIGIUSEPPE JA, NELSON WG, SEIFTER EJ, BOITNOTT JK, MANN RB: Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J. Clin. Oncol. (1994) 12:2573–2579.
  • ••This is the only published series documenting the efficacy of chemotherapy treatment for intravascular lymphomatosis, a rare disease.
  • DEBIAIS S, BONNAUD I, COTTIER JP et al.: A spinal cord intravascular lymphomatosis with exceptionally good outcome. Neurology (2004) 63:1329–1330.
  • SCOTT TF, HOGAN EL, CARTER TD, GAREN PD, BRILLMAN J: Primary intracranial meningeal lymphoma. Am. J. Med. (1990) 89:536–538.
  • LACHANCE DH, O'NEILL BP, MACDONALD DR et aL: Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology (1991) 41:95–100.
  • MOORE KR, BLUMENTHAL DT, SMITH AG, WARD JH: Neurolymphomatosis of the lumbar plexus: high-resolution MR neurography findings. Neurology (2001) 57:740–742.
  • HOFFMAN PM, MCKELVIE P, HALL AJ, STAWELL RJ, SANTAMARIA JD: Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (2003) 17:513–521.
  • ZALDI VAR RA, MARTIN DF, HOLDEN JT, GROSSNIKLAUS HE: Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis. Ophthalmology (2004) 111:1762–1767.
  • PONZONI M, ARRIGONI G, GOULD VE et al.: Lack of CD29 (131 integrin) and CD54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Human Pathol. (2000) 31:220–226.
  • •This publication reports a lack of specific adhesion molecules as a potential migrational defect for intravascular lymphomatosis.
  • LEVITT LJ, DAWSON DM, ROSENTHAL DS, MOLONEY WC: CNS involvement in non-Hodgkin's lymphoma. Cancer (1980) 45:545–552.
  • LIANG R, CHIU E, LOKE SL: Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. HematoL Oncol. (1990) 8:141–145.
  • HOFFMANN C, TABRIZIAN S, WOLF E et al.: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS (2001) 15:2119–2127.
  • ••This publication documents the decliningincidence of primary CNS lymphomas in AIDS patients due to highly active antiretroviral therapy.
  • PELS H, MONTESINOS-RONGEN M, SCHALLER C et al.: Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma. Neurology (2004) 63:167–169.
  • •This is the first paper demonstrating the donality of primary CNS lymphoma specimens from initial diagnosis and subsequent recurrence.
  • KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495–497.
  • ••This is a seminal paper that led to the Nobel Prize for monoclonal antibody.
  • DE HAARD HJ, VAN NEER N, REURS A et al.: A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. (1999) 274:18218–18230.
  • BACA M, PRESTA LG, O'CONNOR SJ, WELLS JA: Antibody humanization using monovalent phage display. J. Biol. Chem. (1997) 272:10678–10684.
  • ••This paper described phage displaytechnology for rapid screening of antibodies with high target specificity.
  • GAO C, MAO S, LO CH et al.: Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Proc. Arad Acad. Sci. (1999) 96:6025–6030.
  • GAO C, MAO S, KAUFMANN G et aL:A method for the generation of combinatorial antibody libraries using pIX phage display. Proc. Nail. Acad. Sci. (2002) 99:12612–12616.
  • RADER C, CHERESH DA, BARBAS CF: A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc. Arad Acad. Sci. (1998) 95:8910–8915.
  • BROGGEMANN M, NEUBERGER MS: Strategies for expressing human antibody repertoires in transgenic mice. ImmunoL Today (1996) 17:391–397.
  • KARPAS A, DEMUCHEVA A, CZEPULKOWSKI BH: A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc. Nail. Acad. Sci. (2001) 98:1799–1804.
  • ••This is an important paper for developingfully human monoclonal antibodies for therapeutic use.
  • BATCHELOR T, CARSON K, O'NEILL A et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J. Clin. Oncol. (2003) 21:1044–1049.
  • •This paper documented the use of methotrexate 8 g/m2.
  • DEANGELIS LM, SEIFERHELD W, SCHOLD SC, FISHER B, SCHULTZ CJ: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J. Clin. OncoL (2002) 20:4643–4648.
  • •This is a multi-institutional study using combined modality methotrexate 2.5 g/m2, followed by consolidative radiotherapy and high-dose cytarabine.
  • BLAY JY, BOUHOUR D, CARRIE C et al.: The C5R Protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. j Clin. OncoL (1995) 86:2922–2929.
  • GUHA-THAKURTA N, DAMEK D, POLLACK C, HOCHBERG FH: Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J. NeurooncoL (1999) 43:259–268.
  • FISHER RI, GAYNOR ER, DAHLBERG S et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. EngL J. Med. (1993) 328:1002–1006.
  • VELASQUEZ WS, MCLAUGHLIN P, TUCKER S et al.: ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J. Clin. OncoL (1994) 12:1169–1176.
  • LACHANCE DH, BRIZEL DM, GOCKERMAN JP et al.: Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology (1994) 44:1721–1727.
  • •This paper documents the lack of efficacy of CHOP for CNS lymphomas.
  • SCHULTZ C, SCOTT C, SHERMAN W et al.: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group Protocol 88-06. J. Clin. OncoL (1996) 14:556–564.
  • RUBINSTEIN LJ, HERMAN MM, LONG TG, WILBUR JR: Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer (1975) 35:291–305.
  • POSNER JB: Neurologic complications ofcancer. FA Davis Company, Philadelphia, PA, USA (1995) 282–310.
  • MALONEY DG, SMITH B, ROSE A: Rituximab: mechanism of action and resistance. Semin. OncoL (2002) 29:2–9.
  • RAIZER JJ, DEANGELIS LM, ZELENETZ AE, LAUREN AE: Activity of rituximab in primary central nervous system lymphoma PCNSL. Proc. Am. Soc. Clin. OncoL (2000) 19:166a.
  • RUHSTALLER TW, AMSLER U, CERNY T: Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann. Oncol. (2000) 11:374–375.
  • HARJUNPAA A, WIKLUND T, COLLAN J et al.: Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk. Lymphoma (2001) 42:731–738.
  • RUBENSTEIN JL, COMBS D, ROSENBERG J et aL: Rituximab therapy for CNS lymphoma: targeting the leptomeningeal compartment. Blood (2003) 101:466–468.
  • ••This paper documented the CSFpenetration of rituximab in patients receiving intravenous administration of the drug.
  • SCHULZ H, PELS H, SCHMIDT-WOLF I et aL: Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica (2004) :89:753–754.
  • PELS H, SCHULZ H, MANZKE O et aL: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J. NeurooncoL (2002) 59:213–216.
  • ANGELOV L, VOGELBAUM MA, BARNETT GH et aL: Primary central nervous system lymphoma: response to temozolomide therapy. Neuro-OncoL (2003) 5:347.
  • QUINN J, REARDON D, RICH J et aL: Phase II treatment of adults with newly diagnosed, progressive, or recurrent primary central nervous system lymphoma with Temodar. Neuro-OncoL (2003) 5:354.
  • RENI M, MASON W, ZAJA F et al.: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur. J. Cancer (2004) 40:1682–1688.
  • WONG ET, TISHLER R, BARRON L, WU JK: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer (2004) 101:139-145. This is the first paper documenting the use of combination rituximab and temozolomide in patients with CNS lymphomas, including those with poor renal functions.
  • WONG E, BARRON L, BLOOM J, WU J: Durable responses from immunochemotherapy with rituximab and temozolomide in patients with central nervous system lymphomas. Cancer Biother. Radiopharm. (2004) 19:514.
  • ENTING RH, DEMOPOULOS A, DEANGELIS LM, ABREY LE: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2004) 63:901–903.
  • DILLMAN RO: Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J. Clin. OncoL (2002) 20:3545–3557.
  • HERNANDEZ MC, KNOX SJ: Radiobiology of radioimmunotherapy with ibritumomab tiuxetan (Zevalin). Semin. OncoL (2003) 30:6–10.
  • KEATING MJ, FLINN I, JAIN V et aL: Therapeutic role of alemtuzumab (campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554–3561.
  • OSTERBORG k DYER MJS, BUNJES D et aL: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J. Clin. OncoL (1997) 15:1567–1574.
  • RAI KR, FRETER CE, MERCIER RJ et al.: Aletuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. j Clin. OncoL (2002) 20:3891–3897.
  • KHORANA A, BUNN P, MCLAUGHLIN P, VOSE J, STEWART C, CZUCZMAN MS: A phase II multicenter study of campath-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk. Lymphoma (2001) 41:77–87.
  • LUNDIN J, OSTERBORG A, BRITTINGER G et aL: Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphoma: a phase II multicenter study. J. Clin. OncoL (1998) 16:3257–3263.
  • SATO S, MILLER AS, INAOKI M et aL: CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity (1996) 5:551–562.
  • ENGEL P, NOJIMA Y, ROTHSTEIN D et al.: The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. j Immunol (1993) 150:4719–4732.
  • LEONARD JP, COLEMAN M, KETAS JC: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. (2003) 21:3051–3059.
  • LEONARD JP, COLEMAN M, KETAS JC et al.: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res. (2004) 10:5327–5334.
  • MILLER DH, KHAN OA, SHEREMATAWA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. J. Med. (2003) 348:15–23.
  • O'CONNOR PW, GOODMAN A, WILLMER-HULME AJ et al.: Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology (2004) 62:2038–2043.
  • TEROL MJ, LOPEZ-GUILLERMO A, BOSCH F et al.: Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J. Clin. Oncol. (1999) 17:1869–1875.

Websites

  • http://www.fda.gov/cder/drug/advisory/ natalizumab.htm FDA PUBLIC HEALTH ADVISORY: Suspended marketing of Tysabri (natalizumab).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.